INVESTOR INTELLIGENCE
Thursday, November 19, 2026The Daily Briefing
Biotech news, drug catalysts, and the market moves that matter.
REGULATORY INTELLIGENCE
Regeneron wins FDA approval for first RNAi drug in its portfolio
The Alnylam collaboration brings a new competitor to the myasthenia gravis market.
BioPharma Dive Nov 19REGN
THE NEWSROOM
Latest Intelligence
ResearchBIOPHARMA DIVE · Nov 18
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
Proponents of compounding argue it increases access, lowers prices and helps patients who may need individualized versions of a drug. But there are serious concerns, experts said at the HLTH conference.
Read report
RegulatoryBIOPHARMA DIVE · Nov 18
White House pulls nomination for FDA nominee Overton
The sudden end of Heidi Overton’s candidacy likely ensures a Democrat-controlled Congress will choose the FDA’s next leader — but shouldn’t disrupt the agency, analysts say.
Read report
BusinessBIOPHARMA DIVE · Nov 18
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
Read report